ALX Oncology Insider Purchases 92,233 Shares; Lettmann Boosts Stake

Rhea-AI Filing Summary

ALX Oncology Holdings (ALXO) Form 4: Chief Executive Officer and director Jason Lettmann made open-market purchases of the issuer's common stock on 09/16/2025 and 09/17/2025. He acquired a total of 92,233 shares at weighted average prices of $1.066 and $1.0805 respectively. Following the transactions, the reporting person beneficially owned 305,121 shares. The filing discloses that the reported prices are weighted averages from multiple transactions within stated price ranges and that additional breakdowns are available on request. The Form 4 was signed by an attorney-in-fact on 09/18/2025.

Positive

• Insider purchases of 92,233 shares reported, indicating increased ownership by the CEO/director
• Beneficial ownership increased to 305,121 shares after the transactions
• Transparent pricing disclosure: weighted-average prices and price ranges were provided with offer to supply transaction-level details

Negative

• None.

Insights

Securities Analyst

TL;DR Insider purchases of 92,233 shares increased the CEO's beneficial ownership to 305,121 shares.

This Form 4 documents direct open-market acquisitions by the CEO and company director on consecutive days, totaling 92,233 common shares at weighted average prices of $1.066 and $1.0805. The filing reports resulting beneficial ownership of 305,121 shares. From a securities-analyst perspective, revealed additions to insider holdings are a clear change in ownership position that market participants can quantify precisely from the filing. The disclosures include weighted-average price ranges and an offer to provide transaction-level details upon request, which supports traceability of the reported averages.

Corporate Governance Expert

TL;DR Reported purchases are routine Section 16 disclosures increasing insider stake; no departures or governance actions disclosed.

The Form 4 is a routine compliance filing showing beneficial ownership changes by an officer/director. It records acquisitions via open-market purchases and confirms direct ownership form. There are no changes in officer status, no option exercises, and no derivative transactions reported. The signature by power of attorney is noted. For governance analysis, this filing signals a higher insider share count but contains no governance actions or new commitments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		P		21,070	A	$1.066(1)	233,958	D
Common Stock	09/17/2025		P		71,163	A	$1.0805(2)	305,121	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.09, inclusive.

	/s/ Shelly Pinto, by power of attorney	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ALXO report in this Form 4?

The CEO/director, Jason Lettmann, purchased a total of 92,233 shares on 09/16/2025 and 09/17/2025 as reported on the Form 4.

How many ALXO shares does the reporting person own after these transactions?

Following the reported purchases, the reporting person beneficially owned 305,121 shares.

What prices were paid for the ALXO shares in the Form 4?

The filing shows weighted-average prices of $1.066 (09/16/2025) and $1.0805 (09/17/2025); footnotes state individual trades ranged from $1.05 to $1.09.

Were any derivative or option transactions reported for ALXO in this Form 4?

No. Table II (derivative securities) contains no reported transactions; only non-derivative common stock purchases are disclosed.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Shelly Pinto, by power of attorney, on 09/18/2025.